About Aldevron
Aldevron is a company based in Fargo (United States) founded in 1998 was acquired by Danaher in June 2021. The company has 747 employees as of December 31, 2022. Aldevron has completed 1 acquisition, including Genovac. Aldevron offers products and services including Plasmid DNA Manufacturing, mRNA Manufacturing, and Protein and Enzyme Manufacturing. Aldevron operates in a competitive market with competitors including Senti Biosciences, Poseida Therapeutics, KBI Biopharma, ADARx Pharmaceuticals and CRISPR Therapeutics, among others.
- Headquarter Fargo, United States
- Employees 747 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aldevron, Llc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aldevron
Aldevron offers a comprehensive portfolio of products and services, including Plasmid DNA Manufacturing, mRNA Manufacturing, and Protein and Enzyme Manufacturing.
Produces high-quality DNA for research and clinical applications.
Offers scalable RNA production with encapsulation options.
Creates custom proteins for diagnostics and therapy uses.
People of Aldevron
Unlock access to complete
Unlock access to complete
Funding Insights of Aldevron
Investors in Aldevron
Aldevron has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Danaher, EQT and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by private equity firm TA.
|
Locked | Locked | Locked | |
|
EQT is recognized as a global investment organization focused on value creation.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Aldevron
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aldevron
Aldevron has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Genovac.
Investment portfolio details for Aldevron
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Antibody discovery platforms and technologies are developed for protein targets.
|
Locked | Locked | 1999 | Locked |
Complete acquisition details for Aldevron
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Aldevron
Detailed financials for Aldevron
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aldevron Comparisons
Peer comparison for Aldevron
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aldevron
Aldevron operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, Poseida Therapeutics, KBI Biopharma, ADARx Pharmaceuticals and CRISPR Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Provider of protein formulation, process & cell line development, and cGMP services
|
|
| Locked | Locked | Locked |
Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts
|
|
| Locked | Locked | Locked |
Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing.
|
Detailed competitors of Aldevron
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aldevron
Complete news archive for Aldevron
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aldevron
Aldevron was founded in 1998 and raised its 1st funding round 9 years after it was founded.
Aldevron is headquartered in Fargo, United States. It is registered at Fargo, North Dakota, United States.
As of Dec 31, 2022, the latest employee count at Aldevron is 747.
Founded in 1998 and based in Fargo, United States, Aldevron operates in the biotechnology sector, focusing on nucleic acid and protein manufacturing. Plasmid DNA production has been completed for over 70,000 projects using proprietary methods, supporting research, preclinical, clinical, and diagnostic needs. Services include gene-to-protein manufacturing for custom enzymes, recombinant antibodies, and proteins, alongside antibody development through genetic, protein, and peptide immunization for reagents, diagnostics, and therapeutics.
Aldevron's top competitors include CRISPR Therapeutics, Senti Biosciences and KBI Biopharma.
Aldevron offers Plasmid DNA Manufacturing, mRNA Manufacturing, and Protein and Enzyme Manufacturing.
Aldevron has made 1 acquisition, including Genovac.
Aldevron has 4 investors. Key investors include Danaher, EQT, HHS, and TA Associates.